The cause of neonatal hyperbilirubinemia could not be identified in 64 infants (70.3%), ABOblood group incompatibility in 14.3% and Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency in 8.8%.
In contrast to human leukocyte antigen (HLA) matching, ABO-blood group incompatibility plays a minor role in the success of allogeneic hematopoietic stem cell transplantation (HSCT).
The exclusions were premature infants, an infant with congenital syphilis, low-birth-weight infants, infants with ABOblood group incompatibility, infants with 3-thalassemia, infants with hemoglobin E heterozygote or homozygotes, glucose-6-phosphate dehydrogenase-deficient infants, and infants with fetomaternal hemorrhage.
We studied 57 children with ABOblood group incompatibility, 118 children with type 1 diabetes, and 98 age- and sex-matched unrelated healthy controls from Linköping.
Data on 477 patients with hematologic malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings were analyzed for correlation between donor-recipient ABOblood group incompatibility and the development of elevated bilirubin levels (over 17 mmol/l) after transplantation.